Functional Fluidics has developed a suite of proprietary flow based assays that measure adhesion & thrombosis in whole blood.
We enable our pharmaceutical and academic partners to predict, select, and monitor a variety of emerging and established blood function therapies.
We specialize in the development and standardization of clinical blood function assays to assess individual patient response to our partners’ therapies.
The clinical pain and fatigue characteristic of sickle cell disease is difficult to objectively quantify. Clinicians cannot depend on their physical exam, imaging studies, or laboratory data to validate claims of pain by their patients. This challenge often creates physician and patient dissatisfaction, and makes it difficult to assess individual patient response to SCD modifying therapy in clinical trials. Biomarkers associated with cellular adhesion, inflammation, coagulation, anemia/hemolysis, cellular aggregates, microparticles and nitric oxide metabolism may help to objectively assess patient-reported outcomes (PROs) and response to disease modifying therapy. There is an urgent need for validated biomarkers in sickle cell disease that facilitate open communication between the healthcare team, industry, and individuals with SCD. We will highlight the current “state of the art” in the application of biomarkers and surrogate endpoints as applied to SCD in this educational session.
1. Learn the principles of functional biomarkers and their applications to sickle cell disease.
2. Learn how novel functional biomarkers can be applied to better understand the relationship between SCD biology, clinical manifestations, and patient experience.
3. Learn how novel biomarkers and surrogate endpoints can be incorporated into clinical trials of SCD-modifying agents.
4. Understand how SCD biomarkers and surrogate endpoints are evaluated from a regulatory perspective.
Ahmed Daak, MD, MSc, Ph.D.
Vice President of Medical Research and Clinical Development Sancilio Pharmaceuticals Company (SCI)
Research Professor
Center of Molecular Biology and Biotechnology (CMBB) Florida Atlantic University (FAU)
